Welcome to our dedicated page for CervoMed SEC filings (Ticker: CRVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CervoMed Inc. filings document a clinical-stage biotechnology issuer focused on neflamapimod and age-related brain disorders. Form 8-K reports include Regulation FD disclosures, press release exhibits, operating and financial results, and updates on clinical studies such as RewinD-LB in dementia with Lewy bodies, pharmacokinetic work, biomarker analyses, and ALS platform inclusion.
Proxy materials describe shareholder voting matters, board and governance practices, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also identifies CRVO common stock on the Nasdaq Capital Market and provides capital-structure, business-development, and financial-position disclosures relevant to CervoMed's drug-development model.
CervoMed Director Jane H. Hollingsworth received a stock option grant following her election to the company's board of directors at the 2025 Annual Meeting of Stockholders. The transaction details include:
- Grant of options to purchase 8,100 shares of common stock
- Exercise price set at $6.52 per share
- Options granted on June 23, 2025 with expiration on June 23, 2035
- Vesting schedule: Monthly over one year in equal 1/12th increments
- Vesting begins June 30, 2025, subject to continued service
The stock options were granted under the company's 2025 Equity Incentive Plan in accordance with their non-employee director compensation policy. The Form 4 was filed by William R. Elder as attorney-in-fact for Hollingsworth.
CervoMed Director and 10% owner Sylvie Gregoire received a stock option grant following her election to the company's board of directors at the 2025 Annual Meeting of Stockholders. The transaction details include:
- Grant of options to purchase 8,100 shares of common stock
- Exercise price set at $6.52 per share
- Options granted on June 23, 2025 with expiration on June 23, 2035
- Vesting schedule: Monthly over one year in equal 1/12th increments starting June 30, 2025
- Grant made under the company's 2025 Equity Incentive Plan per non-employee director compensation policy
The options are subject to continued service through applicable vesting dates. The filing was signed by William R. Elder as attorney-in-fact for Gregoire on June 25, 2025.